Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics Inc has developed a differentiated pipeline focused on the treatment of seizures, highlighted by two epilepsy programs with potential first-in-class mechanisms and one with a potential best-in-class mechanism. The company's full-year 2026 net loss estimate has narrowed to $0.40, suggesting improved financial health and operational efficiencies. Furthermore, the rational design of OV329 to optimize GABA levels positions it as a promising candidate with enhanced safety and tolerability compared to existing therapies, which could lead to significant clinical success and positively impact future forecasts.

Ovid Therapeutics faces significant risks that could negatively impact its stock performance, particularly the inability to secure a viable clinical and regulatory strategy for its lead candidate, soticlestat, in Dravet Syndrome, along with the potential for reduced market viability for the product. Additionally, setbacks in other pipeline candidates such as OV329, OV350, and OV4071 pose further challenges for the company, while partnership risks related to its collaboration with Takeda could adversely affect its financial stability. The company reported a net loss of $0.14 per share for 1Q25, which aligns closely with analyst estimates, yet this continued loss alongside anticipated dilution raises concerns about the long-term financial viability of Ovid Therapeutics.